Digital biomarkers for Alzheimer’s disease: the mobile/ wearable devices opportunity

By L. Kourtis, Oliver B. Regele, Justin M. Wright, Graham B. Jones. npj Digital Medicine, 2019

407 citations recorded by the source corpus.

Alzheimer’s Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. A growing body of evidence indicates that cognitive, behavioral, sensory, and motor changes may precede clinical manifestations of AD by several years. Existing tests designed to diagnose neurodegenerative diseases, while well-validated, are often less effective in detecting deviations from normal cognitive decline trajectory in the earliest stages of the disease. In the quest for gold standards for AD assessment, there is a growing interest in the identification of readily accessible digital biomarkers, which harness advances in consumer grade mobile and wearable technologies. Topics examined include a review of existing early clinical manifestations of AD and a path to the respective sensor and mobile/wearable device usage to acquire domain-centric data towards objective, high frequency and passive digital phenotyping.

Subfields: Cognitive Neuroscience, Psychiatry and Mental health, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/2e39d357ed11a5634db1df4dbe5a8aac9de44c1c